AbbVie Pays Capsida $70M to Expand Gene Therapy Alliance to Eye Diseases
AbbVie turned to Capsida Biotherapeutics two years ago for help delivering gene therapies into the brain. That partnership is ongoing, but the pharmaceutical giant now wants to leverage its partner’s technology for delivery of…
Continue Reading
